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KEY POINTS 
 
Question: Does the provision of healthcare costs influence clinicians’ prescribing choices for 
antibiotics and inhalers? 
 
Findings: Provision of cost information resulted in a transient, non-sustained drop in weekly 
institutional spending on antibiotics and no change in inhaled corticosteroids expenditure. The 
introduction of new clinical prescribing guidelines for inhaled corticosteroids was associated with a 
substantial decrease in weekly costs for this medication category. 
 
Meaning: Provision of cost information at the point of prescribing had no sustained impact on 
weekly antibiotic or inhaled corticosteroid costs. The introduction of new clinical guidelines for 
inhaled corticosteroids during the study period was associated with a drop in weekly expenditure 
for these medications. This approach may have more leverage in modifying clinical decision-
making than the provision of cost-feedback. 
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ABSTRACT 
 
Importance: Providing cost feedback has been demonstrated to decrease demand from 
clinicians. 
 
Objective: We tested the hypothesis that providing the cost of drugs to clinicians would modify 
total expenditure. 
 
Design: A prospective study design with a step-wise intervention. 
 
Setting/Participants: Individuals who were admitted to the XXX from November 2013 to 
November 2015 under the physicians. 
 
Intervention: The cost of all antibiotics and inhaled corticosteroids was added to the electronic 
prescribing system. 
 
Main outcomes: The weekly cost for antibiotics and inhaled corticosteroids in the intervention 
period compared to baseline. 
 
Results: Mean weekly expenditure on antibiotics per patient decreased by £3.75 (95% confidence 
intervals CI: -6.52 to -0.98) after the intervention from a pre-intervention mean of £26.44, and then 
slowly increased subsequently by £0.10/week (95%CI: +0.02 to +0.18). Mean weekly expenditure 
on inhaled corticosteroids per patient did not substantially change after the intervention (-£0.03, 
95%CI: -0.06 to -0.01 after the intervention from a pre-intervention mean of £5.29 per person).  
 
New clinical guidelines for inhaled corticosteroids were associated with a decrease in weekly 
expenditure. 
 
Conclusions and relevance: Provision of cost feedback resulted in no sustained change in 
institutional expenditure. However, clinical guidelines have potential for modifying clinical 
prescribing behaviour. 
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Increasing demand for health care has led to a need for strategies to rationalise unnecessary 
demand, without reducing the quality of heathcare provision. There is variation in the cost of 
treating similar conditions between individual clinicians 1, which may represent a degree of sub-
optimal usage of health care resources. This is probably because physicians’ choice of medication 
is predominantly determined by heterogeneous past clinical experiences as well as local and 
national guidelines.  
 
Behavioural insight theory suggests that knowledge of psychological processes may be utilised to 
design interventions that enable doctors to make more informed decisions 2,3. This approach is 
light touch, with no element of obligation for those who are happy with their current practice. An 
example of this approach is the provision of extra information to clinicians, not with the intention of 
directing the clinician in decision making (potentially reducing their autonomy and clinical 
obligations to the patient), but simply informing them of the cost of this decision. We have 
previously added the cost of a commonly used blood test to the reports that clinicians receive and 
observed a 32% decrease in demand over 12 months 4. Testing this approach in other areas of 
healthcare is important, as it is low-cost and easily scalable if demonstrated to be effective in 
modifying demand safely. 
 
The purpose of the current study was to extend this cost-feedback approach to prescription drugs 
in a hospital setting. Specifically, we used electronic prescribing software to provide the cost of all 
antibiotics and corticosteroid inhalers to clinicians, and evaluated the impact of this intervention 
using a prospective study design. These interventions were selected as there are a number of 
options in each therapeutic category available to prescribers, and hence this permitted testing of 
the hypothesis that provision of cost information will modify choice of medication. During the period 
of this prospective study, new clinical guidelines were introduced to help physicians in their choice 
of inhaled corticosteroids. As a consequence, we were also able to explore the efficacy of a 
different non-nudge intervention on clinical decision-making. 
 
Methods 
Study population 
The study population consisted of all individuals who were admitted to the XXX and discharged by 
the medical general physicians who care for adults between November 2013 and November 2015. 
The XXX is a busy acute medical hospital that admitted 140,960 individuals in 2014. The study 
was an evaluation of a health service modification and no ethical approval was required. The study 
was designed as a single intervention that was added to the existing framework of healthcare 
professionals (including microbiologists and pharmacists) that support clinical decision making. 
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Intervention 
The XXX uses iSoft Electronic Prescribing and Administration software to permit electronic 
prescribing of drugs. This has a setting that permits the cost of the drug to be added to the display 
that the prescribing clinician sees immediately prior to selecting the medication of choice. The 
prescribing clinician only sees the cost of the antibiotic or inhaled corticosteroid selected as 
demonstrated in Figure 1. To provide a comprehensive list of medications, costs for every 
antibiotic (cost per day) and inhaled corticosteroids (cost per puff) listed in the March-September 
2014 edition of the British National Formulary were provided by the XXX pharmacy department 
including adjustment for the extra costs of administering intravenous drugs 5. They were then 
added to the prescribing software. The intervention was implemented on the 8th November 2014. 
 
During the period of the study, generic inhaled corticosteroids became available at the XXX during 
the first 6 months of 2015, and new guidelines for the use of inhaled corticosteroids by clinicians 
were independently introduced by the respiratory medicine department in May/June 2015. These 
promoted the use of the cheaper generic medications where possible. This change became 
evident when the weekly cost data were analysed (Figure 2), and it was evident that an external 
change had modified inhaled corticosteroid usage in the institution. 
 
Data 
The data collection period spanned 11th November 2013 to 2nd November 2015. Weekly data on 
all prescribed drugs were collected from the electronic prescribing system along with the number 
of individuals who were prescribed those drugs. The data from the preceding 52 weeks were 
compared with the 52 weeks after the intervention was implemented. 
 
The prescribing data were combined with the data on drug costs to calculate the total weekly 
expenditure on antibiotics and inhaled corticosteroids. Data on the total weekly numbers of 
patients on both therapeutic categories (antibiotics and inhaled corticosteroids) was also collected 
to permit adjustment for clinical activity in the statistical analysis by estimating a cost per patient. 
 
Statistical analysis 
We used segmented regression analyses to evaluate the effect of the intervention on a) total 
weekly expenditure on antibiotics and inhalers and b) weekly per patient expenditure on antibiotics 
and inhalers. The impact on oral doxycycline capsules was also modelled, as this is a relatively 
cheap but commonly used treatment for respiratory infection that we hypothesised would increase 
in prescribing frequency once prescribing costs were made available to physicians. Segmented 
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regression is a powerful interrupted time series method which can identify whether an intervention 
introduced at a single, known point in time had an immediate or delayed impact on the outcome 
measure and whether it was a transient or long-term effect over time. 6  
 
Parsimonious models were identified by backward elimination, dropping any parameters that were 
not significant at the 5% significance level.6,7 All of the parsimonious models were checked to see 
whether there was any autocorrelation; the correlation between successive observations. using 
the autocorrelation function (ACF), which plots the residuals from the segmented regression 
analysis. Stata software (Texas, USA) was used for the statistical analysis. 
 
 
Results 
Over the study period the mean numbers of individuals who were prescribed antibiotics and 
corticosteroids were 428 and 55 individuals per week respectively. The total weekly expenditure 
per patient for both antibiotics and inhalers over the period of study are shown in Figure 2. The 
mean weekly expenditure on antibiotics per patient was at £26.44 in the baseline period, and 
£25.40 in the post-intervention period (Table 1). Comparable expenditure for inhaled 
corticosteroids was also lower in the post-intervention period (£4.17 per patient per week), 
compared to the baseline period (£5.29 per patient per week). This decrease in the weekly cost of 
inhaled corticosteroids was largely due to a change in local prescribing policy from June 2015 
onwards and further analysis of this period is therefore adjusted for this event by fitting a dummy 
variable in the inhaler models. 
 
The results of the segmented regression analysis are presented in Table 1, and allow more 
detailed analysis of the time course of changes in the expenditure after the intervention was 
implemented. Per patient expenditure on antibiotics demonstrated an immediate decrease after 
the intervention, (£3.75 per patient per week or 14% baseline, p=0.008) followed by an increasing 
trend (£0.10 per patient week or 0.4% baseline p=0.015). There was an immediate increase in 
weekly prescribing of doxycycline capsules, a cheaper oral antibiotic, of 18% (confidence 
Intervals: CI: 15 to 26) from a baseline of 1.78 pence per patient per week after the intervention. 
(Table 1, Figure 3). 
 
For both overall inhaler spend and inhaler spend per patient, there was no statistically significant 
underlying trend, and no change in trend post-intervention. There was a small change in trend in 
spending on inhalers, such that weekly per patient spend was decreasing by 3p per week. 
Following a change in local prescribing policy in June 2015, the drop in weekly expenditure on 
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inhalers was 58p for per patient spend and £203 for total inhaler spend per week  (representing a 
65% drop from an unadjusted mean of £311 in the period prior to the local policy change). 
 
 
Conclusions 
This is the first study to prospectively explore the impact of providing the cost of antibiotics and 
inhaled corticosteroids to clinicians in a busy acute medical hospital in the United Kingdom. There 
was an immediate increase in prescriptions for doxycline by 18%, which is a relatively cheap 
option when treating respiratory infection, but this did not translate into a sustained decrease in 
overall weekly expenditure for antibiotics, which was the primary outcome of interest. There was 
no substantial change in expenditure for inhaled corticosteroids that could be attributed to the 
intervention, but a change in local clinical protocols for inhaled corticosteroids that was 
independent of our intervention and promoted generic alternatives was associated with a decrease 
in weekly expenditure of these medications. 
 
By adding the costs of the drugs of interest so that they were clearly visible to the prescribing 
clinician, we can be confident that the intervention was implemented successfully, as it was 
impossible to prescribe the drugs without seeing the price once the intervention was in place 
(Figure 1). Our use of total institutional expenditure on medications as the primary outcome 
measure is a strength and this represents a composite macroeconomic measure that is pertinent 
to efficient healthcare delivery. A further strength of the study was our ability to collect electronic 
data on all drugs prescribed in the XXX, thus providing assurance that we obtained complete data 
on prescribing activity. By studying this population over a period of one year before and after the 
intervention, we can be confident that seasonal variation does not confound our analysis. Studying 
for a longer period is unlikely to be helpful as demographic changes may start to impact on our 
study population and we are unable to adjust for disease severity. There is one limitation of our 
intervention which is that the costs of the drug are only visible once that drug has been selected, 
and not alongside other therapeutic options. Hence, information about the cost of the medication is 
provided by our intervention, but not an immediate cost comparison with alternative drugs. 
Provision of direct cost comparisons between drugs is not a practical option as the decision to 
prescribe the medication is generally made at the patient’s bedside and the prescribing is done 
subsequently, often elsewhere. This division of workload may contribute to the absence of any 
substantial sustained impact on total medication selection, as the person who makes the decision 
may not be the person who prescribes the drug and hence is exposed to the cost information. In 
addition, there are many antibiotics that can be selected to treat a clinical scenario, and comparing 
them all while attending the demands of a busy healthcare setting is not a feasible option. 
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It is surprising that there are no prior studies of the impact of adding price to commonly used 
medications on clinician decision making. This is probably a consequence of the challenge of 
rigorously evaluating change within healthcare settings, where many factors can impact on the 
demand for healthcare, and the ‘system’ remains in constant dynamic flux. As a consequence, our 
choice of the before/after or step-change regression model is probably the optimal study design 
that works in the ‘real world’ of applied health services research, as other options such as the 
randomized controlled trial are not either appropriate or deliverable in this context 8. By knowing 
the exact date of the intervention, we are able to assess the change in prescribing patterns in the 
following weeks. It is evident that there was a change in physician behaviour from the 18% 
increase in prescribing of doxycline immediately after our cost-pricing intervention was 
implemented. This is a large increase in selection of a cheaper but effective antibiotic option that 
did not occur by chance, and hence provides evidence that our drug costs were observed by the 
prescribing doctor. This is important, as the negative results of the intervention were clearly not a 
consequence of the intervention not being seen by the clinicians. It is also important to note that 
this is pragmatic health services research that tested a simple hypothesis and was delivered with a 
limited budget. As a consequence, we were unable to follow up individual clinicians to ask what 
they thought of the intervention, although the increase in prescribing cheaper antibiotics 
immediately after the intervention suggest that they saw it. As with any new intervention, these 
interventions underwent a risk analysis to ensure that no harm was inadvertently delivered. There 
were no adverse events reported and future studies in this area should also consider similar 
measures. 
 
The impact of adding the price transparency to antibiotics on demand was biphasic. There was an 
initial immediate decrease of 14% from baseline in cost per patient per week, but was followed by 
a small weekly increase in costs over the following 12 months of 0.4% the baseline value per 
week. This represents a reversal of the initial effect that we are unable to explain, but is an 
important factor in the consideration of these data. It is possible that the presentation of the price 
displays could be optimized and even varied to prevent familiarisation resulting in ‘alert blindness’, 
and that this may improve awareness of the cost ‘message’ although we were constrained by the 
electronic prescribing software in the presentational options available. As can be seen from Figure 
1, our cost data were clearly available to the prescribing clinician. While alternative strategies to 
optimise provision of the display of cost information could be considered in the future, it is 
important to be mindful that the primary purpose of electronic prescribing software is the safe 
prescribing of medications, and we did not want our cost feedback to detract from this. In addition, 
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we were unable to deliver qualitative research to assess clinicians’ perspectives on the provision 
of health care costs due to budgetary constraints. 
 
Consideration of the context of this study is important in interpreting the generalisability of the 
results. The study was set in a busy teaching hospital where clinicians assess and treat patients 
according to their clinical need, and there is no payment by the patient to contribute to their 
healthcare costs. Hence, while our observations may be applicable to other similar nationally 
funded health care systems, they may not be so generalizable to healthcare systems where 
healthcare management decisions and hence costs may also be influenced by the patients’ ability 
to pay or where medications are rationed as a consequence of scarcity or economic necessity. 
 
This work builds on our previous study, which demonstrated that adding the institutional cost to C 
reactive protein results was associated with a 32% decrease in demand over 52 weeks 4, although 
this was not observed in recent data from the USA 9. We are not aware of any comparable studies 
that have prospectively studied the impact of provision of cost information for commonly used 
drugs on subsequent selection by clinicians. Conventional economic theory suggests that most 
individuals are influenced to some degree by costs, but applying this to medical decision-making is 
challenging and controversial. This is because physicians’ choice of antibiotic is predominantly 
determined by clinical experience as well as local guidelines that already take into consideration 
both local patterns of microbial resistance to antibiotics and cost. Many established antibiotics 
have similar institutional costs, and the mode of delivery (oral versus intravenous) can be an 
important determinant in total cost once this is added into the retail price. However, although 
stepping down from intravenous antibiotics to oral antibiotics does vary depending on the day of 
the week 10 (and hence medical staffing levels), there was no impact of our intervention on total 
costs. Control of inappropriate antibiotic prescribing has been a priority area for the XXX to reduce 
complications such as Clostridium difficile gastro-intestinal infection and it is possible that the use 
of antibiotics in this hospital has reached a level where there is limited scope for improvement. 
Hence, these findings are probably generalisable to institutions with strong existing antibiotic 
guidelines that are actively promoted and supervised. 
 
By delivering this evaluation of a cost-information intervention at the same time as a change in 
clinical guidelines for the use of inhaled corticosteroids, we inadvertently are able to observe a 
natural experiment where the impact of one passive ‘nudge’ intervention (cost-feedback) can be 
compared with a second more directive approach (clinical guidelines). We are cautious in our 
interpretation of these data as it represents a post hoc analysis that is derived from a necessity to 
explain the step-change decrease in weekly expenditure on inhaled corticosteroids data rather 
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than an a priori hypothesis. However, the implementation of new prescribing guidelines for inhaled 
corticosteroids does appear to be associated with a substantial decrease in the costs of 
prescribing these medications and supports the use of local protocols in promoting efficient 
prescribing. 
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Figure 1. Example of drug costing on electronic prescribing system 
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Figure 2. Change in cost of total antibiotics and total inhalers per patient per week 
 
 
  
Vertical line represents intervention 
 
* represents introduction of inhaled corticosteroid protocol 
  
* *
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Figure 3. Change in cost of doxycycline capsules per patient per week 
 
 
 
Vertical line represents intervention 
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Table 1. Segmented regression analysis of XXX drug cost data 
 Pre-
intervention 
mean 
(unadjusted) 
Post-intervention 
mean 
(unadjusted) 
β1 - Baseline trend 
(95% CI) 
β2 - Step level change β3 - Change in 
trend  
Total antibiotics 
spend per week (£) 
10,719 11,260 -43.58 
(-43.58 to -19.60) 
p<0.001 
+2807.50 
(+ 1367.83 to +4247.07) 
p<0.001 
- 
Antibiotics spend per 
patient per week (£) 
26.44 25.40 - -3.75 
(-6.52 to -0.98) 
p=0.008 
+0.10 
(+0.02 to +0.18) 
p=0.015 
100mg Oral 
doxycycline capsules 
spend per patient per 
week (£) 
0.020 0.023 - +0.003 
(+0.001 to +0.005) 
p<0.001 
- 
Total inhaler spend 
per week (£) 
309.29 227.74 - - - 
Inhaler spend per 
patient per week (£) 
5.29 4.17 - - - 0.03 
(-0.06 to -0.01) 
p=0.11 
  
β1: weekly change in spending before intervention 
β2: step change in weekly spend after intervention 
β3: absolute change in trend in weekly spend after intervention, compared with baseline trend 
 
β1+β3 = β4 post-intervention slope. 
Inhaler models include a dummy variable to adjust for a change in local prescribing policy 
Only statistically significant variables are included in the parsimonious models. Gaps in the table 
reflect that variables were not significant and were not include in the final model. 
CI: Confidence intervals 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
